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The relation between baseline clinical variables and subse- 
quent mortality was examined in 295 patients with mild to 
moderate heart failure who participated in a multicenter 
trial comparing the effect on treadmill exercise tolerance of 
captopril, digoxin and placebo given in addition to a 
diuretic drug. At baseline study, all patients had a left 
ventricular ejection fraction 540%; 81% were in New 
York Heart Association functional class II. The etiology of 
heart failure was ischemic in 62% and nonischemic in 38%. 
During an average follow-up period of 16 months, 47 
patients (16%) died and 24 deaths were classified as sud- 
den. By univariate analysis, left ventricular ejection frac- 
tion, ventricular premature beat frequency, couplet fre- 
quency, ventricular tachycardia frequency, functional 
class, treadmill exercise time and nonischemic heart disease 
were statistically associated with mortality. With multiple 
logistic regression analysis, left ventricular ejection fraction 
was identified as the variable most closely associated with 
total mortality (p = 0.006). Twenty-seven percent of pa- 
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tients with an ejection fraction 520% died compared with 
7% with an ejection fraction 230%. Ventricular tachycar- 
dia frequency on Halter monitoring was independently 
associated with both total mortality (p = 0.008) and sudden 
death (p = 0.003). Patients with a ventricular tachycardia 
frequency of >0.088 events/h had a mortality rate of 34% 
compared with 12% in those without ventricular tachycar- 
dia. 
In the multivariate model, functional class (p = 0.02) 
and etiology of nonischemic heart disease (p = 0.04) 
remained as independent predictors of mortality, whereas 
treadmill exercise duration did not. The mortality rate was 
23% in patients with nonischemic heart disease; it was 12% 
in patients with congestive heart failure on the basis of 
coronary artery disease. These data allow the identilication 
of high risk patients and subgroups, and should prove 
useful in designing future trials examining mortality in 
heart failure. 
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Recent clinical trials (I .2) suggest that a significant reduction 
in mortality in patients with congestive heart failure is an 
achievable goal, and a major focus of current research is the 
delineation of patient characteristics predictive of a fatal 
outcome. In previous studies, several clinical and laboratory 
abnormalities have been variably associated with reduced 
survival in specific groups of patients. These include indexes 
relating to cardiac pump dysfunction, such as left and right 
ventricular ejection fraction (I .3-S), cardiac index, left ven- 
tricular filling pressure and systemic vascular resistance 
(691, as well as the degree of functional impairment as 
assessed by New York Heart Association functional class 
(8.10-12) or by exercise testing (13). Other factors reflecting 
disease etiology (8.14). the occurrence of spontaneous 
(15,16) or provoked ventricular arrhythmias (17.18) and the 
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extent of neurohumeral activation (9,19,20) have also been 
implicated as important prognostic factors. 
A prospective clinical trial, the primary results of which 
were recently reported (21). was conducted to compare the 
efficacy of captopril, digoxin and placebo in improving 
treadmill exercise tolerance in diuretic-treated patients with 
mild to moderate heart failure. Because it was not designed 
as a mortality trial, the sample size and follow-up period 
were insufficient to assess the impact of these treatments on 
survival. The overall size of the study and the scope of 
baseline data acquisition, however, afforded an opportunity 
to examine the relation between a large number of baseline 
clinical variables and the subsequent mortality rate in a well 
defined group of patients with heart failureAata that might 
be of value in the design of future studies. The results of this 
examination are summarized in this report. 
Methods 
exercise tolerance, baseline clinical and laboratory data 
acquired in all subjects included: complete history and 
physical examination, left ventricular ejection fraction at 
rest, 24 hour ambulatory electrocardiogram (ECG). chest 
X-ray film. I2 lead ECG and blood chemistry profile. New 
York Heart Association class assignment was modified to 
include a subdivision of class II patients into those with 
slight (class IIS) and moderate (class IIM) limitation of 
physical activity. Left ventricular ejection fraction was 
determined with equilibrium-gated radionuclide angiogra- 
phy. Twenty-four hour ambulatory ECGs were computer 
analyzed at a central facility with use of the Cardio-Data 
Mark 111 arrhythmia analysis system (Medical Monitors, 
Inc., Wyncote. Pennsylvania). Rates of ventricular prema- 
ture beats. couplets (two consecutive ventricular premature 
beats) and ventricular tachycardia (three or more consecu- 
tive ventricular premature beats) were calculated. The am- 
bulatory ECG results were not available to investigators and 
did not influence subsequent treatment decisions. 
Study patients. Three hundred patients younger than 75 
years of age were recruited at 27 centers in the United 
States, Canada and New Zealand. Entry criteria included a 
clinical diagnosis of congestive heart failure, left ventricular 
ejection fraction 540% and abnormal treadmill exercise 
capacity limited by dyspnea or fatigue, or both. Exercise 
capacity was assessed with use of a modified Naughton 
protocol (2 min stages). Subjects were eligible for admission 
if total exercise time exceeded 4 min but was reduced 
relative to predetermined limits for age and gender (22). 
Patients with heart failure resulting from coronary artery 
disease, primary myocardial disease or cardiomyopathy 
secondary to surgically corrected valvular heart disease 
were eligible for admission. The diagnosis of coronary heart 
disease was established by a history of typical angina pec- 
toris, documented myocardial infarction or angiographic 
demonstration of significant coronary atherosclerosis. Sub- 
jects whose exercise tolerance was limited by ischemic chest 
pain or who required antianginal drug therapy other than 
infrequent sublingual nitroglycerin were excluded. Concom- 
itant therapy with beta-adrenergic blocking agents, vasodi- 
lators or calcium antagonists precluded admission to the 
study. Other exclusion criteria included myocardial infarc- 
tion within the preceeding 8 weeks, significant arterial hy- 
pertension (blood pressure >I60490 mm Hg) despite diuretic 
therapy, atrial fibrillation and significant renal impairment 
(serum creatinine ~2.0 mgldl). Approval of the institutional 
review board at each participating center was obtained 
before initiation of the study. 
At the conclusion of the 2 week lead-in period, patients 
were randomized to receive captopril, 50 mg three times 
daily, digoxin. 0.25 mg (dosage optimized by serum digoxin 
determinations) or placebo in addition to furosemide. The 
follow-up period ranged from 6 to 30 months. Although some 
patients were removed from assigned treatment because of 
clinical deterioration, all deaths in the randomized patients 
were ascertained. The circumstances of death were indepen- 
dently reviewed by members of a committee, and those 
deaths occurring without premonitory symptoms or within 
I h of the onset of new symptoms were classified as sudden 
and unexpected. When unanimity of classification of death 
did not occur, a group vote and decision was made. 
Statistical methods. The association of individual pre- 
treatment variables with total mortality and sudden death, 
adjusted for treatment effects, was obtained from separate 
logistic regression analyses, each model containing indicator 
variables representing treatment assignment and a single 
pretreatment variable. The following variables were exam- 
ined: age, functional class, ejection fraction, exercise time, 
etiology of heart failure, treatment group, frequency of 
ventricular premature beats, couplets and ventricular tachy- 
cardia events and serum concentrations of sodium, potas- 
sium and magnesium. All variables were treated as continu- 
ous covariables with the exception of etiology of heart 
failure. Rates of ventricular premature beats, couplets and 
ventricular tachycardia were logarithmically transformed 
after the addition of a constant (23). Functional class was 
scored as 1 [I], IIS [2], IIM [2.5] and III [3]. 
Protocol. After informed consent was obtained, inotropic The subset of variables simultaneously exhibiting signif- 
agents and vasodilators were withdrawn in patients receiving icant nssociations with mortality. hence providing indepen- 
them; diuretic treatment with furosemide was optimized dent predictive information, was culled from the initial group 
based on clinical response. Previously prescribed antiar- of variables with use of stepwise multiple logistic regression 
rhythmic therapy with agents other than disopyramide or analysis. Both forward and backward selection routines 
amiodarone was maintained. In addition to assessment of converged on the same variable subset. 
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Table 1. Patient Baseline Characteristics 
No. of patients 
Mean age (yr) 
Gender (R male) 
CHF duration (yr) 
Cardiothoracic ratio 
Third heart sound (%I 
CHF etiology (%I 
Ischemic 
Nonischemic 
295 
56.8 
83 
2.95 
0.53 
38 
62 
38 
Exercise time (SI 
Ejection fraction (‘%) 
NY HA class (%l 
I 
IIS 
IlM 
III 
VPBih 
Couplets (W) 
VT (%) 
558 
25 
37 
44 
13 
14.2 
59 
36 
Table 2. Association of Baseline Variables With Mortality: 
Simule Reeression 
Total Mortality Sudden Death 
(P) (P) 
Ejection fraction (%I <0.0001 0.001 
VPB frequency* 0.07 NS 
Couplet frequency* 0.002 0.04 
VT frequency* 0.0004 0.001 
NYHA class 0.001 0.06 
Exercise lime Is) 0.005 NS 
NlHDt 0.008 0.01 
CHF = congestive heart fadure: NYHA = New York Heart Awxiation: 
IIM and IIS = moderate and slight. respectively. limitation of physical 
*Log transformed, tCoded as: 0 = ischemic heart disease, I = nonisch- 
activity: VPB = ventricular premature beat: VT = ventricular tachycardia. 
emit heart disease INIHD). NS = nut significant: other abbreviations as in 
Table I. 
Results 
Selected baseline patient characteristics (Table 1). TWO 
hundred ninety-five patients had complete baseline data and 
were the basis of all subsequent analyses. Their mean age 
was 56.8 years. The etiology of heart failure, determined 
historically, was ischemic in 62% and nonischemic in 38%. 
Mean exercise duration was 558 s. and left ventricular 
ejection fraction averaged 25%. Eighty-one percent of pa- 
tients were classified in New York Heart Association func- 
tional class II. Of these, 37% were in class IIS (slight 
functional limitation) and 44% were in class IIM (moderate 
functional limitation). Geometric mean ventricular prema- 
ture beat frequency was 14.2/h. Fifty-nine percent of pa- 
tients exhibited at least one ventricular couplet, and 36% at 
least one episode of nonsustained (duration <30 s) ventric- 
ular tachycardia. Eighteen percent of patients were receiving 
antiarrhythmic drug therapy at baseline study. 
Mortality. During an average follow-up period of 16 
months, 47 patients (16%) of the randomized study patients 
died. Twenty-four of these deaths were classified as sudden 
and unexpected. There was no significant difference in the 
mortality rate among treatment groups, and the groups were 
pooled for all statistical analyses. 
Predictors of total mortality and sudden death (Tables 2 
and 3). The univariate association of individual baseline 
variables (which had a statistical significance of p < 0.10) 
with total mortality and sudden death is shown in Table 2. 
Left ventricular ejection fraction proved to be the most 
statistically powerful predictor of total mortality (p < 0.0001) 
and was also related to the occurrence of sudden death (p = 
0.01). Three variables derived from ambulatory ECG moni- 
toring were related to mortality rate. The frequencies of 
ventricular couplets and ventricular tachycardia were statis- 
tically associated with both total mortality (p = 0.002 for 
couplet frequency and p = 0.0004 for ventricular tachycar- 
dia) and sudden death (p = 0.04 for ventricular couplets and 
p = 0.001 for ventricular tachycardia); ventricular tachycar- 
dia frequency was the stronger predictor. The association 
between baseline ventricular premature beat frequency and 
total mortality was of borderline significance (p = 0.07) and 
this variable was not related to sudden death. Other univari- 
ate predictors of total mortality included functional class 
(p = 0.001). total exercise duration (p = 0.005) and nonisch- 
emit heart failure etiology (p = 0.008). Nonischemic etiology 
was also related to the occurrence of sudden death (p = 
0.01); the association of functional class with sudden death 
was of borderline significance (p = 0.06). No significant 
association was observed among a variety of other variables 
including age, serum sodium concentration, or serum potas- 
sium concentration and either total mortality or sudden 
death. 
Left ventricular function (Table 3). The independent re- 
lation of the just cited variables with mortality as determined 
by stepwise multiple logistic regression analysis is shown in 
Table 3. Left ventricular ejection fraction remained the most 
important independent predictor of total mortality (p = 
0.006). whereas its association with sudden death was of 
borderline significance (p = 0.06). The relation between 
baseline left ventricular ejection fraction and mortality is 
illustrated in Figure I. Eighty-eight patients had an entry 
ejection fraction ~20% and exhibited an overall mortality 
rate of 27% during the follow-up period. This contrasted with 
a 7% mortality rate seen in subjects with a baseline ejection 
fraction >30%. Patients with values in the 21% to 30% range 
demonstrated an intermediate mortality rate of 14%. Be- 
Table 3. Association of Baseline Variables With Mortality: 
MultiDIe Logistic Regression 
Total Mortality Sudden Death 
(PI (P) 
Ejection fraction (‘%\ a.006 0.06 
NYHA class 0.02 NS 
NlHD: 0.04 0.03 
VT frequency* 0.008 0.003 
*Log transformed: tcoded as: 0 = ischemic heart disease. 1 = nonisch- 
emit heart disease. Abbreviations as in Tables 1 and 2. 
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m Sudden Death 
Non-Sudden Death 
< 20% 21-30% 31-40% 
LVEF 
Figure 1. Relation between baseline left ventricular ejection fraction 
CLVEF) and subsequent mortality rate. The average follow-up 
period was 16 months. 
tween 25% and 50% of deaths in each subgroup were sudden 
and unexpected. 
Ventricular arrhythmias (Table 3). The frequency of ven- 
tricular tachycardia provided prognostic information con- 
cerning total mortality (p = 0.008) and sudden death (p = 
0.003) in addition to that provided by left ventricular ejection 
fraction. Ventricular premature beat and couplet frequencies 
were not significantly associated with either outcome event 
after adjustment for ejection fraction and ventricular tachy- 
cardia frequency. Ventricular tachycardia frequency was the 
single most important predictor of sudden death in this 
cohort; its importance as a mortality predictor is shown in 
Figure 2. In 189 subjects without ventricular tachycardia at 
baseline study, total mortality rate was 12%. In 106 subjects 
with ventricular tachycardia, the median hourly ventricular 
tachycardia frequency was 0.088 events/h (2. I events/day). 
Total mortality rate (13%) was not increased in patients 
exhibiting ventricular tachycardia event rates below the 
median, although the fraction of deaths classified as sudden 
Figure 2. Relation between baseline ventricular tacbycardia (VT) 
event rate and subsequent mortality rate. 
Sudden Death 
Non-Sudden Death 
NoVl c.OEB/hr 
VTlHr 
r.OWhr 
60 
m Sudden Death 
Non-Sudden Death 
0 
VT OCCUVWG No Yes No Yes No Yes No Yes 
~wiagv lschemic Non-lschemic lschemic Non-lschemic 
Figure 3. Relation between baseline left ventricular ejection fraction 
(LVEF), occurrence of ventricular tachycardia (VT) and heart 
failure etiology and subsequent mortality rate. 
was greater. Subjects with a ventricular tachycardia fre- 
quency above the median had a mortality rate of 34%, almost 
triple that of patients without ventricular tachycardia or with 
rare ventricular tachycardia events. Sudden, presumably 
arrhythmic death occurred in 16% of patients in that sub- 
group compared to 5% in patients without ventricular tachy- 
cardia at baseline. 
Functional class. In the multivariate model, New York 
Heart Association functional class remained as an indepen- 
dent predictor of total mortality, whereas total treadmill 
exercise duration did not. Patients classified in class I or IIS 
had a total mortality rate of 8% compared with 20% in 
patients in class IIM and 26% in patients in class III. Neither 
functional class nor exercise duration correlated with sudden 
death. 
Heart failure etiology. Etiology of nonischemic heart 
failure in this group of patients (from which angina-limited 
patients were excluded) was a significant independent pre- 
dictor of both total mortality (p = 0.04) and sudden death 
(p = 0.03). Twenty-three percent of patients with nonisch- 
emit heart disease died during the follow-up period, com- 
pared with 12% of patients with heart failure resulting from 
coronary artery disease. The interactive nature of the rela- 
tion between left ventricular ejection fraction, etiology of 
heart failure and occurrence of ventricular tachycardia is 
illustrated in Figure 3. In patients with an ejection fraction 
>25%, neither ventricular tachycardia occurrence nor heart 
failure etiology appeared to exert a significant influence on 
mortality events. In the subgroup with more severely com- 
promised left ventricular function, however, the combina- 
tion of ventricular tachycardia and etiology of nonischemic 
heart disease identified a subgroup with a very high mortality 
rate of 47%, most of whom died suddenly. 
Discussion 
Despite a recent decline in total cardiovascular mortality 
in the United States, the prevalence of congestive heart 
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failure has continued to increase markedly and mortality 
remains high despite significant advances in the symptomatic 
effectiveness of drug therapy (24.25). Death in patients with 
this syndrome usually is either a result of progressive 
hemodynamic deterioration or a sudden event, presumably 
related to lethal ventricular arrhythmias. Numerous studies 
have sought to delineate patient characteristics of prognostic 
importance. Most are based on analysis of patients in 
functional classes HI and IV enrolled in clinical trials eval- 
uating the effectiveness of drug therapy in advanced conges- 
tive heart failure or referred to centers specializing in the 
treatment of severe heart failure. The present study ad- 
dresses a group of patients with symptomatically less severe 
disease. Eighty-one percent were in functional class II and 
all were admitted to the study only if able to tolerate 
treatment with diuretic drugs alone during a 2 week preran- 
domization period. The overall mortality rate of 16% over I6 
months is relatively low for heart failure studies and is 
consistent with the degree of symptomatic severity. 
Left ventricular function as a predictor of mortality. Left 
ventricular ejection fraction proved to be the most important 
independent determinant of total cardiac mortality in pa- 
tients with mild to moderate congestive heart failure. Al- 
though the overriding influence of left ventricular function 
on prognosis in survivors of acute myocardial infarction and 
other patient subgroups with coronary artery disease is well 
established (5,26,27), its prognostic importance in patients 
with congestive heart failure has recently been questioned. 
Even though some investigators (1.3,4) have observed a 
relation between left ventricular ejection fraction and sur- 
vival, this finding has not been consistent (IO). In a recent 
review, Frdnciosa (7) suggested that most of the relation 
between left ventricular ejection fraction and survival in 
patients with coronary disease derives from comparisons of 
patients with normal and abnormal values, and that there 
might be no relation with survival in symptomatic patients 
with uniformly reduced left ventricular ejection fraction. Our 
data indicate that this is not the case in subjects with mild to 
moderate heart failure included in this study, all of whom 
demonstrated a baseline ejection fraction <40%. 
Importance of functional class. The relation between ejec- 
tion fraction and survival may be dependent on symptomatic 
status. Wilson et al. (10) examined a group of patients with 
symptomatically refractory congestive heart failure and did 
not observe a correlation between ejection fraction and 
mortality rate, although mean left ventricular ejection frac- 
tion in their patients was similar to that found in the present 
study (27% versus 25%). In contrast, analysis of the results 
of the Veterans Administration Vasodilator Heart Failure 
Trial (1). in which both the symptomatic status and mean left 
ventricular ejection fraction (30%) were comparable with 
those found in this study, resulted in the conclusion that 
ejection fraction was an important determinant of survival 
regardless of assigned drug therapy. Factors responsible for 
the highly variable degree of functional impairment observed 
in subjects with similar levels of left ventricular dysfunction 
are poorly understood. but appear to be important in deter- 
mining long-term survival in patients with congestive heart 
failure. 
Integrated functional status, as measured by New York 
Heart Association functional class. was a significant mortal- 
ity predictor in this group of patients even after statistical 
correction for other baseline variables, including left ventric- 
ular ejection fraction. Previous studies (7) have suggested 
that functional class is prognostically useful primarily in 
identifying subjects exhibiting the greatest degree of inca- 
pacity and subsequent mortality, but is not useful in strati- 
fying less severely ill patients. In the present study, a 
modification of the New York Heart Association schema 
was adopted, whereby patients in class II were divided into 
those with slight and moderate functional limitation. An 
increased mortality rate was found at each incremental step 
in the modified schema, suggesting that this methodology 
may enhance the usefulness of functional classification in 
predicting mortality. 
It is noteworthy that, in contrast to functional class, 
treadmill exercise capacity was not an independent predictor 
of the overall mortality rate. This finding tends to validate 
the importance of assessing overall clinical status as opposed 
to determining a subject’s ability to perform a single speci- 
fied task. It is possible, however, that more sophisticated 
measurements of functional capacity derived from exercise 
testing, such as maximal oxygen uptake, would have been 
more predictive than the duration of treadmill exercise, a 
measurement subject to variation related to factors other 
than cardiac performance. 
Ventricular arrhythmias in patients with heart failure. It 
is increasingly appreciated that sudden cardiac death occurs 
frequently in patients with congestive heart failure and 
accounts for between 22% and 86% of deaths in published 
series (28). In this study, 50% of deaths were classified as 
sudden. Frequent ventricular premature beats and nonsus- 
tained ventricular tachycardia are observed in a large pro- 
portion of patients with severe heart failure (10,15,16,29,30). 
Several studies (3,15,16) have concluded that advanced 
grades of asymptomatic arrhythmia identify patients at high 
risk for total mortality and sudden death. Others have found 
no relation (29.31) or have determined that these arrhyth- 
mias are merely markers of disease severity and provide no 
independent prognostic information (10). The present study 
confirms the importance of arrhythmia variables derived 
from Holter ECG monitoring as predictors of both total 
mortality and sudden death in patients with mild to moderate 
heart failure. Analyzed as continuous variables, ventricular 
premature beat, couplet and ventricular tachycardia fre- 
quencies were univariate predictors of total mortality; 
couplet and ventricular tachycardia frequencies were al- 
so significant univariate predictors of sudden death. By 
JACC Vol 14. No. 3 
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multivariate analysis, ventricular tachycardia frequency 
proved to be an independent prognostic factor in determin- 
ing total mortality and was second only to ejection fraction in 
the statistical strength of association. When sudden deaths 
were included in the model, ventricular tachycardia fre- 
quency was the single most important identifiable factor. 
Ventricular tachycardia frequency. In determining prog- 
nosis, ventricular tachycardia frequency proved to be more 
useful than the presence or absence of ventricular tachycar- 
dia. Inclusion of this factor as a continuous variable in the 
statistical model may explain the discrepancy between these 
results and some earlier negative studies that examined 
ventricular tachycardia as a yes/no variable. Thus, in this 
study, patients exhibiting fewer than two episodes of ven- 
tricular tachycardia daily did not incur a significant incre- 
ment in mortality risk, whereas a more frequent occurrence 
of ventricular tachycardia resulted in an almost threefold 
increase in total mortality. Our results are comparable with 
those obtained by Meinertz ct al. (IS), who also utilized 
quantitative arrhythmia variables and noted a highly signif- 
icant association between ventricular premature beat. cou- 
plet and ventricular tachycardia frequencies and sudden 
death in patients with idiopathic dilated cardiomyopathy. 
Their data indicate that patients with mild to moderate heart 
failure exhibiting more than two episodes of ventricular 
tachycardia daily constitute a high risk subgroup. In the 
future, this finding may have important implications in 
making treatment decisions regarding the institution of an- 
tiarrhythmic therapy in this category of patients with con- 
gestive heart failure. At the present time, however, no 
definitive recommendations can be made in view of the 
absence of convincing data that document a reduction in the 
incidence of sudden death in patients with heart failure 
treated prophylactically with currently available antiarrhyth- 
mic drugs. 
Heart failure etiology and prognosis. Several reports 
(8,14,31) have suggested that etiology may be a significant 
prognostic factor in patients with heart failure. In most, but 
not all series. patients with heart failure as a result of 
coronary heart disease have exhibited poorer long-term 
survival compared with those with nonischemic cardiomy- 
opathy. The opposite result was found in our cohort. The 
reasons for this discrepancy are not clear. It should be noted 
that our study relied on historical and noninvasive data, 
rather than coronary arteriography. in establishing an isch- 
emit etiology and some patients may have been misclassi- 
fied. The present results do suggest that patients with stable, 
clinically diagnosed coronary disease and mild to moderate 
heart failure as a result of prior myocardial damage have a 
favorable prognosis relative to that of patients with nonisch- 
emit disease and similar symptomatic status. 
Implications for future clinical trials. Considerable atten- 
tion is currently focused on the effectiveness of various drug 
treatment strategies in improving the mortality rate in pa- 
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tients with heart failure. The results of the present study are 
helpful in allowing clinical identification of patients with an 
increased mortality risk. By delineating high risk subgroups. 
such information can be useful in designing future clinical 
trials. For example, a group of patients in functional class 
IIM or III with a ventricular tachycardia frequency >O.O88/h 
define a group of patients with a mortality rate of 42% over 
I6 months. If only patients with an ejection fraction 520% 
are considered. the projected mortality rate increases to 
50%. In patients with nonischemic cardiomyopathy and 
these characteristics. the estimated mortality rate is 64%. If 
these data arc used to select the admission criteria, it should 
be possible to design statistically powerful mortality studies 
using relatively small sample sizes. 
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